{"name":"BIOGEN IDEC","slug":"biogen-idec","ticker":"","exchange":"","domain":"biogenidec.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":2400000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[{"name":"Tysabri","genericName":"NATALIZUMAB","slug":"natalizumab","revenue":1600000000,"yoyGrowth":0,"percentOfTotal":66.7},{"name":"Plegridy","genericName":"PEGINTERFERON BETA-1A","slug":"peginterferon-beta-1a","revenue":800000000,"yoyGrowth":0,"percentOfTotal":33.3}],"timeline":[{"date":"2004-01-01","label":"Tysabri first approved","drug":"Tysabri","drugSlug":"natalizumab","type":"approval","sentiment":"positive"},{"date":"2014-01-01","label":"Plegridy first approved","drug":"Plegridy","drugSlug":"peginterferon-beta-1a","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":1600000000,"percentOfTotal":66.7,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Tysabri","genericName":"NATALIZUMAB","slug":"natalizumab","indication":"Multiple Sclerosis","status":"marketed","revenue":1600000000}]},{"name":"Neuroscience","slug":"neuroscience","revenue":800000000,"percentOfTotal":33.3,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Plegridy","genericName":"PEGINTERFERON BETA-1A","slug":"peginterferon-beta-1a","indication":"Relapsing remitting multiple sclerosis","status":"marketed","revenue":800000000},{"name":"Spinraza","genericName":"NUSINERSEN","slug":"nusinersen","indication":"Spinal muscular atrophy","status":"marketed"}]}],"pipeline":[{"name":"Tysabri","genericName":"NATALIZUMAB","slug":"natalizumab","phase":"marketed","mechanism":"Natalizumab blocks α4 integrins on leukocytes, preventing their adhesion to VCAM-1 and MAdCAM-1, reducing inflammation in MS and Crohn's disease.","indications":["Multiple Sclerosis","Crohn's Disease"],"catalyst":""},{"name":"Plegridy","genericName":"PEGINTERFERON BETA-1A","slug":"peginterferon-beta-1a","phase":"marketed","mechanism":"Plegridy works by binding to the interferon alpha/beta receptor, which helps to reduce inflammation and slow disease progression in multiple sclerosis.","indications":["Relapsing remitting multiple sclerosis"],"catalyst":""},{"name":"Spinraza","genericName":"NUSINERSEN","slug":"nusinersen","phase":"marketed","mechanism":"Spinraza works by binding to a specific genetic sequence to increase production of a protein that helps maintain muscle function.","indications":["Spinal muscular atrophy"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}